China Will Issue New Fast-Track Procedure For Drug Registration – CDE Official
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - China's State FDA will launch a new fast-track mechanism by year end called the special approval procedure for drug registration to accelerate drug registration, SFDA Center for Drug Evaluation Official Yi Feng, told China Trials 2008 attendees here Nov. 10
You may also be interested in...
AstraZeneca Healthcare Policy Research VP James Cai On Building A CRO Community In China: An Interview With PharmAsia News
Cai talks about the growing CRO landscape in China and how multinational companies can work with local CROs to improve the clinical trial infrastructure.
AstraZeneca Healthcare Policy Research VP James Cai On Building A CRO Community In China: An Interview With PharmAsia News
James Cai, AstraZeneca's VP, Healthcare Policy Research, sat down with PharmAsia News' Shanghai bureau during the China Trials 2008 conference in November to discuss the burgeoning CRO landscape in China and how multinational companies can work with local CROs to improve the clinical trial infrastructure there.
AstraZeneca Healthcare Policy Research VP James Cai On Building A CRO Community In China: An Interview With PharmAsia News
Cai talks about the growing CRO landscape in China and how multinational companies can work with local CROs to improve the clinical trial infrastructure.